NO20044333L - Farmasoytiske kombinasjon for behandling av godartet prostatis hyperplasi eller for langtidsprevensjon av akutt urinretensjon - Google Patents
Farmasoytiske kombinasjon for behandling av godartet prostatis hyperplasi eller for langtidsprevensjon av akutt urinretensjonInfo
- Publication number
- NO20044333L NO20044333L NO20044333A NO20044333A NO20044333L NO 20044333 L NO20044333 L NO 20044333L NO 20044333 A NO20044333 A NO 20044333A NO 20044333 A NO20044333 A NO 20044333A NO 20044333 L NO20044333 L NO 20044333L
- Authority
- NO
- Norway
- Prior art keywords
- long
- pharmaceutical combination
- treatment
- urinary retention
- acute urinary
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2002118392 DE10218392A1 (de) | 2002-04-24 | 2002-04-24 | Verwendung von Arzneimittelkombinationen zur Behandlung von benigner Prostatahyperplasie |
DE2002118611 DE10218611A1 (de) | 2002-04-25 | 2002-04-25 | Verwendung einer Tamsulosin enthaltenden Arzneimittelkombination zur Behandlung von benigner Prostatahyperplasie |
PCT/EP2003/004034 WO2003090753A1 (fr) | 2002-04-24 | 2003-04-17 | Combinaison pharmaceutique pour le traitement de l'hyperplasie prostatique benigne ou pour la prevention a long terme de la retention urinaire aigue |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20044333L true NO20044333L (no) | 2004-11-09 |
Family
ID=29271571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20044333A NO20044333L (no) | 2002-04-24 | 2004-10-12 | Farmasoytiske kombinasjon for behandling av godartet prostatis hyperplasi eller for langtidsprevensjon av akutt urinretensjon |
Country Status (22)
Country | Link |
---|---|
US (2) | US20030225118A1 (fr) |
EP (2) | EP1501517B1 (fr) |
JP (1) | JP2005524693A (fr) |
CN (1) | CN1646135A (fr) |
AT (1) | ATE361075T1 (fr) |
AU (1) | AU2003227643A1 (fr) |
BR (1) | BR0309435A (fr) |
CA (1) | CA2479992A1 (fr) |
CY (1) | CY1107674T1 (fr) |
DE (1) | DE60313603T2 (fr) |
DK (1) | DK1501517T3 (fr) |
EA (1) | EA008377B1 (fr) |
ES (1) | ES2287474T3 (fr) |
HR (1) | HRP20040994A2 (fr) |
IL (1) | IL163976A0 (fr) |
MX (1) | MXPA04010408A (fr) |
NO (1) | NO20044333L (fr) |
NZ (1) | NZ536514A (fr) |
PL (1) | PL371430A1 (fr) |
PT (1) | PT1501517E (fr) |
RS (1) | RS92304A (fr) |
WO (1) | WO2003090753A1 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0309435A (pt) * | 2002-04-24 | 2005-02-15 | Boehringer Ingelheim Pharma | Combinação farmacêutica para o tratamento de hiperplasia prostática benigna ou para a prevenção a longo prazo de retenção urinária aguda |
KR20060124603A (ko) * | 2003-11-03 | 2006-12-05 | 베링거 인겔하임 인터내셔날 게엠베하 | 베타-3-아드레날린 수용체 효능제 및 알파 길항제 및/또는5-알파-리덕타제 억제제를 함유하는 약제학적 조성물 |
US7601994B2 (en) * | 2003-11-14 | 2009-10-13 | Semiconductor Energy Laboratory Co., Ltd. | Display device and method for manufacturing the same |
WO2006055659A2 (fr) * | 2004-11-15 | 2006-05-26 | Smithkline Beecham Corporation | Composition pharmaceutique |
CN102309495A (zh) * | 2010-06-30 | 2012-01-11 | 北京润德康医药技术有限公司 | 一种复方制剂及其制备方法 |
WO2012110092A1 (fr) | 2011-02-17 | 2012-08-23 | Synthon Bv | Dérivés de tamsulosine |
BRPI1103204A2 (pt) * | 2011-06-03 | 2014-02-25 | Eurofarma Lab S A | Composição farmacêutica para o tratamento de hiperplasia prostática benigna |
WO2013123965A1 (fr) | 2012-02-20 | 2013-08-29 | Synthon Bv | Formulation pharmaceutique à dose fixe |
US10596127B2 (en) | 2013-03-14 | 2020-03-24 | Wellesley Pharmaceuticals, Llc | Composition for reducing the frequency of urination, method of making and use thereof |
BR102013020508B1 (pt) * | 2013-08-12 | 2021-01-12 | Ems S/A. | Forma de dosagem que compreende um inibidor de esteroide 5-alfa-redutase e um bloqueador alfa, processo para a preparaçãode uma forma de dosagem e uso da forma de dosagem |
ES2555485T1 (es) | 2014-05-26 | 2016-01-04 | Galenicum Health S.L. | Composiciones farmacéuticas que contienen un agente activo |
AU2016331879A1 (en) * | 2015-09-30 | 2018-05-17 | Wellesley Pharmaceuticals, Llc | Composition for reducing the frequency of urination, method of making and use thereof |
US10172910B2 (en) * | 2016-07-28 | 2019-01-08 | Nymox Corporation | Method of preventing or reducing the incidence of acute urinary retention |
CN115969860A (zh) * | 2021-10-14 | 2023-04-18 | 上海汇伦医药股份有限公司 | 一种药物组合物及其用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5391825A (en) * | 1980-02-08 | 1995-02-21 | Yamanouchi Pharmaceutical Co., Ltd. | Sulfamoyl substituted phenethylamine intermediates |
JPS56110665A (en) | 1980-02-08 | 1981-09-01 | Yamanouchi Pharmaceut Co Ltd | Sulfamoyl-substituted phenetylamine derivative and its preparation |
US4760071A (en) | 1984-02-27 | 1988-07-26 | Merck & Co., Inc. | 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors |
IL74365A (en) | 1984-02-27 | 1990-07-26 | Merck & Co Inc | 17beta-(n-t.-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one and pharmaceutical compositions containing it |
US4772475A (en) | 1985-03-08 | 1988-09-20 | Yamanouchi Pharmaceutical Co., Ltd. | Controlled-release multiple units pharmaceutical formulation |
EP0285383B1 (fr) | 1987-04-03 | 1994-03-16 | Merck & Co. Inc. | Traitement des carcinomes prostatiques avec des 17-bêta-n-monosubstitué-carbamoyl-4-aza-5-alpha-androst-1-en-ones |
EP0285382B1 (fr) | 1987-04-03 | 1994-04-13 | Merck & Co. Inc. | Traitement d'alopécia androgénique avec 17-bêta-n-monosubstitué-carbamoyl-4-aza-5-alpha-androst-1-en-3-ones |
IL101243A (en) * | 1991-03-20 | 1999-12-22 | Merck & Co Inc | Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history |
TW369521B (en) | 1993-09-17 | 1999-09-11 | Smithkline Beecham Corp | Androstenone derivative |
TW382595B (en) | 1993-10-15 | 2000-02-21 | Merck & Co Inc | Pharmaceutical composition for use in arresting and reversing androgenic alopecia |
US6423719B1 (en) * | 1999-02-16 | 2002-07-23 | Upsher-Smith Laboratories, Inc. | Method for treating benign prostate hyperplasia |
WO2001021167A1 (fr) * | 1999-09-22 | 2001-03-29 | Merck & Co., Inc. | Traitement des symptomes des voies urinaires basses, et compositions pharmaceutiques a utiliser dans le cadre dudit traitement |
BR0309435A (pt) * | 2002-04-24 | 2005-02-15 | Boehringer Ingelheim Pharma | Combinação farmacêutica para o tratamento de hiperplasia prostática benigna ou para a prevenção a longo prazo de retenção urinária aguda |
-
2003
- 2003-04-17 BR BR0309435-9A patent/BR0309435A/pt not_active Expired - Fee Related
- 2003-04-17 PL PL03371430A patent/PL371430A1/xx not_active Application Discontinuation
- 2003-04-17 JP JP2003587387A patent/JP2005524693A/ja active Pending
- 2003-04-17 ES ES03725053T patent/ES2287474T3/es not_active Expired - Lifetime
- 2003-04-17 CA CA002479992A patent/CA2479992A1/fr not_active Abandoned
- 2003-04-17 AU AU2003227643A patent/AU2003227643A1/en not_active Abandoned
- 2003-04-17 EA EA200401340A patent/EA008377B1/ru not_active IP Right Cessation
- 2003-04-17 IL IL16397603A patent/IL163976A0/xx unknown
- 2003-04-17 AT AT03725053T patent/ATE361075T1/de active
- 2003-04-17 NZ NZ536514A patent/NZ536514A/en unknown
- 2003-04-17 CN CNA038089300A patent/CN1646135A/zh active Pending
- 2003-04-17 EP EP03725053A patent/EP1501517B1/fr not_active Revoked
- 2003-04-17 RS YU92304A patent/RS92304A/sr unknown
- 2003-04-17 PT PT03725053T patent/PT1501517E/pt unknown
- 2003-04-17 DE DE60313603T patent/DE60313603T2/de not_active Revoked
- 2003-04-17 DK DK03725053T patent/DK1501517T3/da active
- 2003-04-17 WO PCT/EP2003/004034 patent/WO2003090753A1/fr active IP Right Grant
- 2003-04-17 MX MXPA04010408A patent/MXPA04010408A/es active IP Right Grant
- 2003-04-17 EP EP06122312A patent/EP1743656A3/fr not_active Withdrawn
- 2003-04-24 US US10/422,509 patent/US20030225118A1/en not_active Abandoned
-
2004
- 2004-10-12 NO NO20044333A patent/NO20044333L/no not_active Application Discontinuation
- 2004-10-22 HR HR20040994A patent/HRP20040994A2/hr not_active Application Discontinuation
-
2007
- 2007-04-06 US US11/697,470 patent/US20070197666A1/en not_active Abandoned
- 2007-06-14 CY CY20071100794T patent/CY1107674T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1743656A3 (fr) | 2007-03-07 |
BR0309435A (pt) | 2005-02-15 |
ATE361075T1 (de) | 2007-05-15 |
WO2003090753A8 (fr) | 2004-11-04 |
HRP20040994A2 (en) | 2005-02-28 |
WO2003090753A1 (fr) | 2003-11-06 |
PL371430A1 (en) | 2005-06-13 |
EP1501517A1 (fr) | 2005-02-02 |
EA200401340A1 (ru) | 2005-06-30 |
DE60313603D1 (de) | 2007-06-14 |
US20030225118A1 (en) | 2003-12-04 |
EA008377B1 (ru) | 2007-04-27 |
PT1501517E (pt) | 2007-05-31 |
US20070197666A1 (en) | 2007-08-23 |
MXPA04010408A (es) | 2005-02-17 |
DE60313603T2 (de) | 2008-01-03 |
JP2005524693A (ja) | 2005-08-18 |
DK1501517T3 (da) | 2007-06-11 |
CN1646135A (zh) | 2005-07-27 |
NZ536514A (en) | 2006-11-30 |
EP1501517B1 (fr) | 2007-05-02 |
CY1107674T1 (el) | 2013-04-18 |
AU2003227643A1 (en) | 2003-11-10 |
RS92304A (en) | 2006-10-27 |
IL163976A0 (en) | 2005-12-18 |
EP1743656A2 (fr) | 2007-01-17 |
ES2287474T3 (es) | 2007-12-16 |
CA2479992A1 (fr) | 2003-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1107674T1 (el) | Φαρμακευτικος συνδυασμος για τη θεραπευτικη αντιμετωπιση της καλοηθους υπερπλασιας του προστατη ή για την μακροπροθεσμη προληψη της οξειας επισχεσης ουρων | |
DK1955700T3 (da) | Terapeutisk behandling af androgenreceptor-betingede lidelser | |
DK0968208T3 (da) | Quinolin- og quinazolin-forbindelser som er nyttige i terapi især til behandling af godartet prostatisk hyperplasia | |
WO2008046083A3 (fr) | Utilisation de composés oxindole comme agents thérapeutiques | |
HUP0100586A2 (hu) | Alsó húgyvezetéki tünetek kezelésére alkalmas gyógyászati készítmények | |
EA200301104A1 (ru) | Антиангиогенная комбинированная терапия для лечения онкологических заболеваний | |
NO20040516L (no) | Kombinasjonsterapi for behandling av kreft. | |
BR9714394A (pt) | Inibidores da atividade enzimática de psa | |
HUP0104688A2 (hu) | Összetételek és eljárások a rákbetegség és a rákbetegséggel kapcsolódó csontveszteség megelőzéséhez és kezeléséhez | |
EP1610778A4 (fr) | Traitement de l'hypertrophie prostatique benigne | |
DK0565296T3 (da) | Anvendelse af melatonin til fremstilling af et lægemiddel til behandling af godartet prostatahyperplasi | |
ATE211921T1 (de) | Verwendung von gonadotropin zur behandlung der gestartigen hypertrophie der prostata | |
ATE250580T1 (de) | Substituierte pyridino-arylpiperazine zur behandlung benigner prostatahyperplasie | |
EA200401100A1 (ru) | 1α-ФТОР-25-ГИДРОКСИ-16,23E-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ | |
WO2007141661A3 (fr) | Compositions galéniques pour la prévention ou le traitement d'une hypertrophie bénigne de la prostate | |
DK1345907T3 (da) | 7-Heterocyclyl-quinolin- og thieno-2,3-B-pyridin-derivater anvendelige som antagonister af gonadotropin-frigörende hormon | |
GB0301016D0 (en) | Treatment of benign prostatic hyperplasia | |
NO975838L (no) | Melatoninagonister for behandling av godartet prostatisk hyperplasi | |
EP1485117A4 (fr) | Methodes de traitement therapeutique de l'hypertrophie benigne de la prostate (bph) | |
SI1501517T1 (sl) | Farmacevtska kombinacija za zdravljenje benigne hiperplazije prostate ali za dolgotrajno preprečevanje akutne retencije urina | |
ECSP982362A (es) | Compuestos de quinolina y quinazolina utiles en terapia | |
DE69807166D1 (de) | Prostata-spezifische Antigen Inhibitore | |
EP1435913A4 (fr) | Methode de traitement d'hyperplasie prostatique benigne et d'autres pathologies prostatiques benignes | |
WO2002077162A3 (fr) | Gene (t23490) associe a l'hyperplasie benigne de la prostate | |
MX9710075A (es) | Antagonistas melatonina para el tratamiento en la hiperplasia prostatica benigna. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |